| Stereochemistry | ABSOLUTE |
| Molecular Formula | C23H20Cl2N4O2S |
| Molecular Weight | 487.402 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN\C(=N/S(=O)(=O)C1=CC=C(Cl)C=C1)N2C[C@@H](C(=N2)C3=CC=C(Cl)C=C3)C4=CC=CC=C4
InChI
InChIKey=AXJQVVLKUYCICH-OAQYLSRUSA-N
InChI=1S/C23H20Cl2N4O2S/c1-26-23(28-32(30,31)20-13-11-19(25)12-14-20)29-15-21(16-5-3-2-4-6-16)22(27-29)17-7-9-18(24)10-8-17/h2-14,21H,15H2,1H3,(H,26,28)/t21-/m1/s1
| Molecular Formula | C23H20Cl2N4O2S |
| Molecular Weight | 487.402 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 1 |
| Optical Activity | UNSPECIFIED |
Ibipinabant (IBI) is an orally active potent cannabinoid-1 receptor (CB1R) antagonist. This drug was studied for the treatment of obesity and psychotic disorders. However, the development of the drug was discontinued in November 2008. Now, ibipinabant is only used for laboratory research, especially structure-activity relationship studies into novel CB1 antagonists.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 25.2 nM [Ki] | |||
PubMed
Patents
Sample Use Guides
5 mg (ST) to 50 mg (LT) Tablet, Oral, Once Daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)
Route of Administration:
Oral
